3/26
06:16 pm
cort
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT
Low
Report
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT
3/26
05:22 pm
cort
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant) [Yahoo! Finance]
Neutral
Report
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant) [Yahoo! Finance]
3/26
04:42 pm
cort
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Low
Report
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
3/26
01:44 pm
cort
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Low
Report
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
3/26
11:28 am
cort
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a "buy" rating on the stock.
Low
Report
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a "buy" rating on the stock.
3/26
10:00 am
cort
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT
3/26
09:00 am
cort
Corcept Therapeutics (CORT) was upgraded by Wolfe Research from "underperform" to "peer perform".
Medium
Report
Corcept Therapeutics (CORT) was upgraded by Wolfe Research from "underperform" to "peer perform".
3/26
05:49 am
cort
Corcept Therapeutics (CORT) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
Corcept Therapeutics (CORT) was upgraded by Truist Financial Corporation to "strong-buy".
3/26
05:03 am
cort
Assessing Corcept Therapeutics (CORT) Valuation After Recent Share Price Weakness And User Fair Value Debate [Yahoo! Finance]
Low
Report
Assessing Corcept Therapeutics (CORT) Valuation After Recent Share Price Weakness And User Fair Value Debate [Yahoo! Finance]
3/25
09:47 pm
cort
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
Medium
Report
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
3/25
09:14 pm
cort
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK [Yahoo! Finance]
Medium
Report
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK [Yahoo! Finance]
3/25
05:01 pm
cort
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday [Yahoo! Finance]
Medium
Report
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday [Yahoo! Finance]
3/25
04:55 pm
cort
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Medium
Report
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
3/25
01:51 pm
cort
Corcept Therapeutics (CORT) had its price target lowered by HC Wainwright from $67.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Corcept Therapeutics (CORT) had its price target lowered by HC Wainwright from $67.00 to $60.00. They now have a "buy" rating on the stock.
3/25
12:43 pm
cort
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Low
Report
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
3/25
09:00 am
cort
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Corcept Therapeutics Incorporated(CORT) Shareholders
High
Report
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Corcept Therapeutics Incorporated(CORT) Shareholders
3/24
10:05 pm
cort
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
High
Report
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
3/24
06:00 pm
cort
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026
High
Report
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026
3/24
04:17 pm
cort
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
High
Report
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
3/24
03:35 pm
cort
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Low
Report
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
3/24
12:30 pm
cort
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Low
Report
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
3/24
12:00 pm
cort
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
3/24
09:00 am
cort
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm
Low
Report
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm
3/24
08:49 am
cort
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately
Low
Report
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately
3/23
11:51 pm
cort
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT
Low
Report
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT